Best Practice & Research Clinical Haematology
Volume 22, Issue 4 , Pages 577-582 , December 2009

Cancer research: from folate antagonism to molecular targets

  • Joseph R. Bertino, MD (Professor, Interim Director)

      Affiliations

    • University Professor of Medicine and Pharmacology, USA
    • Stem Cell Institute of New Jersey, USA
    • Cancer Institute of New Jersey, 195 Little Albany Street, Room 3033, New Brunswick, NJ 08901, USA
    • Corresponding Author InformationCorresponding author. UMDNJ-Robert Wood Johnson Medical School, Department of Molecular Therapeutics, The Cancer Institute of New Jersey, 195 Little Albany Street, Room 3033, New Brunswick, NJ 08901, USA. Tel.: +1 732 235 8510; Fax: +1 732 235 8181.

References 

  1. Osborn MJ, Freeman M, Huennekens FM. Inhibition of dihydrofolic reductase by aminopterin and amethopterin. Proc Soc Exp Biol Med. 1958;97:429–431
  2. O'Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies. J Clin Oncol. 2009;Epub
  3. Wang Y, Zhao R, Goldman ID. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier. Clin Cancer Res. 2004;10:6256–6264
  4. Mitchell MS, Wawro NW, DeConti RC, et al. Effectiveness of high-dose infusions of methotrexate followed by leucovorin in carcinoma of the head and neck. Cancer Res. 1968;28:1088–1094
  5. Berd D, Cornog J, DeConti RC, et al. Long-term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy. Cancer. 1975;35:1050–1054
  6. Bertino JR, Sawicki WL, Moroson BA, et al. 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (tmq), a potent non-classical folate antagonist inhibitor–I effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo. Biochem Pharmacol. 1979;28:1983–1987
  7. Allegra CJ, Kovacs JA, Drake JC, et al. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med. 1987;165:926–931
  8. Lacerda JF, Goker E, Kheradpour A, et al. Selective treatment of SCID mice bearing methotrexate-transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection. Blood. 1995;85:2675–2679
  9. Szelenyi H, Hohenberger P, Lochs H, et al. Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO. Oncology. 2000;58:273–279
  10. Punt CJ, van Maanen L, Bol CJ, et al. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs. 2001;12:193–197
  11. Bertino JR. Modulation of 5-fluorouracil/leucovorin by trimetrexate–did it work?. Ann Oncol. 2002;13:10–11
  12. Chabner BA, Johns DG, Bertino JR. Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity. Nature. 1972;239:395–397
  13. DeAngelis LM, Tong WP, Lin S, et al. Carboxypeptidase G2 rescue after high-dose methotrexate. J Clin Oncol. 1996;14:2145–2149
  14. Capizzi RL. Asparaginase revisited. Suppl: Leuk Lymphoma. 1993;10:147–150
  15. Alt FW, Kellems RE, Bertino JR, et al. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem. 1978;253:1357–1370
  16. Gorlick R, Goker E, Trippett T, et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med. 1996;335:1041–1048
  17. Budak-Alpdogan T, Bertino JR. Chemoprotection by transfer of resistance genes. Methods Mol Biol. 2009;542:661–704
  18. Budak-Alpdogan T, Alpdogan O, Banerjee D, et al. Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. Mol Ther. 2004;10:574–584
  19. Cavazzana-Calvo M, Hacein-Bey S, de Saint BG, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669–672
  20. Noguchi P. Risks and benefits of gene therapy. N Engl J Med. 2003;348:193–194
  21. Deichmann A, Hacein-Bey-Abina S, Schmidt M, et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest. 2007;117:2225–2232
  22. Aiuti A, Cassani B, Andolfi G, et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest. 2007;117:2233–2240
  23. Shou Y, Ma Z, Lu T, et al. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci U S A. 2006;103:11730–11735
  24. Ercikan-Abali EA, Banerjee D, Waltham MC, et al. Dihydrofolate reductase protein inhibits its own translation by binding to dihydrofolate reductase mRNA sequences within the coding region. Biochemistry. 1997;36:12317–12322
  25. Chu E, Takimoto CH, Voeller D, et al. Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro. Biochemistry. 1993;32:4756–4760
  26. Guo W, Healey JH, Meyers PA, et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res. 1999;5:621–627
  27. Goto Y, Yue L, Yokoi A, et al. A novel single-nucleotide polymorphism in the 3'-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin Cancer Res. 2001;7:1952–1956
  28. Mishra PJ, Humeniuk R, Mishra PJ, et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A. 2007;104:13513–13518
  29. Song B, Wang Y, Kudo K, et al. miR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin Cancer Res. 2008;14:8080–8086

PII: S1521-6926(09)00065-6

doi: 10.1016/j.beha.2009.09.004

Best Practice & Research Clinical Haematology
Volume 22, Issue 4 , Pages 577-582 , December 2009

Article Tools

* Image Usage & Resolution